Praxis Precision Medicines, Inc. (PRAX)
264.49
+4.32
(+1.66%)
USD |
NASDAQ |
Oct 20, 16:00
263.01
-1.48
(-0.56%)
After-Hours: 07:09
Praxis Precision Medicines Research and Development Expense (TTM) : 290.71M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 290.71M |
| March 31, 2026 | 284.30M |
| December 31, 2025 | 267.12M |
| September 30, 2025 | 245.90M |
| June 30, 2025 | 221.98M |
| March 31, 2025 | 186.24M |
| December 31, 2024 | 152.41M |
| September 30, 2024 | 114.51M |
| June 30, 2024 | 89.89M |
| March 31, 2024 | 88.25M |
| December 31, 2023 | 86.77M |
| September 30, 2023 | 96.71M |
| June 30, 2023 | 109.89M |
| Date | Value |
|---|---|
| March 31, 2023 | 127.89M |
| December 31, 2022 | 155.04M |
| September 30, 2022 | 170.22M |
| June 30, 2022 | 172.92M |
| March 31, 2022 | 154.98M |
| December 31, 2021 | 120.26M |
| September 30, 2021 | 93.02M |
| June 30, 2021 | 72.66M |
| March 31, 2021 | 56.04M |
| December 31, 2020 | 44.98M |
| September 30, 2020 | 34.40M |
| June 30, 2020 | 30.96M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| BioMarin Pharmaceutical, Inc. | 766.68M |
| Insmed, Inc. | 860.84M |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Xencor, Inc. | 255.76M |